RAD001: Clinical Trials

111 trials of RAD001, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

79 completed, 23 terminated, 4 withdrawn, 3 active not recruiting. 111 Phase 1, 43 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1111Completed 79, Terminated 23, Withdrawn 4, Active not recruiting 3, Recruiting 1, Unknown 1
Phase 243Completed 31, Terminated 10, Unknown 1, Withdrawn 1

Follow RAD001: new trials by email Literature Review of RAD001 trials Research Report on RAD001

Trials (filtered) newest first · largest first

All 111 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
DFF332, RAD001, PDR001 - Carcinoma, Renal Cell
Phase 1TerminatedNovartis Pharmaceuticals402021-11-302026-03-03
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Everolimus, Trametinib - Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma
Phase 1RecruitingUniversity of California, San Francisco502020-12-092026-08-18
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1TerminatedOHSU Knight Cancer Institute22020-04-012024-03-04
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma
Phase 1CompletedPediatric Brain Tumor Consortium222018-01-132021-08-27
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification
Phase 1TerminatedM.D. Anderson Cancer Center842017-10-312026-07-22
RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
RAD001, Placebo - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome
Phase 1 / Phase 2CompletedBoston Children's Hospital462017-06-122025-02-17
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
PDR001, LCL161, Everolimus - Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Phase 1CompletedNovartis Pharmaceuticals2982016-10-142023-01-11
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
Ceritinib, Everolimus, Laboratory Biomarker Analysis - ALK Positive, Locally Advanced Malignant Solid Neoplasm
Phase 1Active not recruitingM.D. Anderson Cancer Center372016-06-222026-11-12
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Brentuximab Vedotin, Everolimus, Laboratory Biomarker Analysis - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Phase 1TerminatedMayo Clinic102016-02-042019-12-12
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
everolimus, eribulin mesylate, pharmacological study - Estrogen Receptor Negative, HER2/Neu Negative
Phase 1CompletedCity of Hope Medical Center272014-11-172026-10-28
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
Everolimus, LDE 225 - Esophageal Cancer
Phase 1CompletedM.D. Anderson Cancer Center252014-11-102020-06-11
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
everolimus, bendamustine hydrochloride - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
Phase 1CompletedUniversity of California, Davis202014-10-012019-01-04
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Everolimus, Enzalutamide - Prostate Cancer
Phase 1CompletedSCRI Development Innovations, LLC382014-10-012021-05-04
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Everolimus, Laboratory Biomarker Analysis, Letrozole - Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive
Phase 1CompletedM.D. Anderson Cancer Center372014-07-172020-12-19
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
TheraSphere, Everolimus, Phone Call - Liver Cancer
Phase 1WithdrawnM.D. Anderson Cancer Center2014-05-012014-07-22
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
AEB071, Everolimus - CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Phase 1CompletedNovartis Pharmaceuticals312013-12-052020-12-19
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
ribociclib (LEE011), Exemestane, Everolimus (RAD001) - Breast Cancer
Phase 1CompletedNovartis Pharmaceuticals1322013-09-062021-04-13
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
RAD001, Imatinib - Chronic Myeloid Leukemia
Phase 1 / Phase 2WithdrawnUniversity of Michigan Rogel Cancer Center2013-09-012015-05-15
Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
RAD001, Gemcitabine, Cisplatin - Metastatic Breast Cancer
Phase 1 / Phase 2TerminatedNational Cancer Center, Korea232013-08-012017-10-03
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
lapatinib ditosylate, everolimus, capecitabine - Central Nervous System Metastases, HER2-positive Breast Cancer
Phase 1 / Phase 2CompletedJonsson Comprehensive Cancer Center92013-06-262019-11-12

Showing 20 of 111. Sign in to see all of them.

Conditions studied

Breast Neoplasms (14)  ·  Neoplasm Metastasis (12)  ·  Neuroendocrine Tumors (8)  ·  Carcinoma, Non-Small-Cell Lung (7)  ·  Hodgkin Disease (7)  ·  Lung Neoplasms (7)  ·  Carcinoma, Renal Cell (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (6)  ·  Lymphoma, Large B-Cell, Diffuse (6)  ·  Lymphoma, Mantle-Cell (6)  ·  Neoplasms (6)  ·  Recurrence (6)  ·  Colorectal Neoplasms (5)  ·  Lymphoma, Follicular (5)  ·  Multiple Myeloma (5)

Sponsors

Novartis Pharmaceuticals (16)  ·  M.D. Anderson Cancer Center (15)  ·  Dana-Farber Cancer Institute (8)  ·  Emory University (7)  ·  Mayo Clinic (7)  ·  Children's Hospital Medical Center, Cincinnati (4)  ·  Fox Chase Cancer Center (3)  ·  Vanderbilt-Ingram Cancer Center (3)  ·  City of Hope Medical Center (2)  ·  Massachusetts General Hospital (2)  ·  National Cancer Institute (NCI) (2)  ·  Roswell Park Cancer Institute (2)  ·  SCRI Development Innovations, LLC (2)  ·  University of California, Davis (2)  ·  University of Utah (2)

Countries

United States (96)  ·  France (8)  ·  Germany (6)  ·  Spain (5)  ·  Belgium (4)  ·  Italy (4)  ·  Netherlands (4)  ·  South Korea (4)  ·  Australia (3)  ·  Hong Kong (3)  ·  Taiwan (3)  ·  China (2)  ·  Denmark (2)  ·  Japan (2)  ·  Brazil (1)

Top investigators

Filip Janku (2)  ·  Ingrid Mayer, MD (2)  ·  Nabil F. Saba, MD (2)  ·  Sunil Sharma, MD (2)  ·  Suresh Ramalingam, MD (2)  ·  Amanda Townsend, MBBS (1)  ·  Andrew X. Zhu, MD, PhD (1)  ·  Barbara Burtness (1)  ·  Bassel El-Rayes, MD (1)  ·  Benjamin Tan, M.D. (1)  ·  Brian Costello (1)  ·  Brian Hill, MD, PhD (1)  ·  Brian Wolpin, MD (1)

Results publications

PMID 21730275, PMID 19192962, PMID 21047224, PMID 22262746, PMID 22736724, PMID 23325902, PMID 23475104, PMID 23580238, PMID 23798472, PMID 24761838, PMID 24912489, PMID 25103371, PMID 25450031, PMID 25900182, PMID 25982012, PMID 26139427, PMID 26381530, PMID 28357727, PMID 29023494, PMID 29451701, PMID 30220708, PMID 30302599, PMID 30424962, PMID 30542377, PMID 31654285, PMID 31703728, PMID 31967673, PMID 32704173, PMID 33055173, PMID 33115815, PMID 33738668, PMID 35594551, PMID 37314501, PMID 39863139

NIH funding

P30CA015083 (3), 2008 (2), P30CA016672 (2), 2004 (1), P30CA008748 (1), P30CA043703 (1), P30CA068485 (1), P30CA072720 (1), R01FD003743 (1), U01CA062461 (1), U01CA069856 (1), U54NS092090 (1), UM1CA081457 (1)